Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that (NYSE: ABBV) appears to have pulled off successfully in recent days.

During 2023 investors have primarily focused on the company's declining revenue and profits, which stem from the loss of patent exclusivity for its top-selling autoimmune-disease drug Humira. AbbVie's share price reflected the concerns.

However, AbbVie just announced two big acquisitions, spurring its stock to rebound somewhat. Is this Dividend King now a no-brainer buy?

Continue reading

Source Fool.com